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Summary The transplantation of the human T-cell acute lymphoblastic leukaemia (T-ALL) cell line HSB-2
into severe combined immunodeficient (SCID) mice was found to produce a disseminated pattern of leukaemia
similar to that seen in man. The intravenous injection of 107 HSB-2 cells was associated with a universally
fatal leukaemia. Histopathological examination of animals revealed the spread of leukaemia initially from
bone marrow to involve all major organs including the meninges. An immunotoxin (HB2-Sap) was construc-
ted by conjugating the anti-CD7 MAb HB2 to the ribosome-inactivating protein saporin. An in vitro protein
synthesis inhibition assay revealed specific delivery of HB2-Sap immmunotoxin (IT) to CD7+ HSB-2 target
cells with an IC50 of 4.5 pM. When SCID mice were injected with 106 HSB-2 cells and then treated 8 days
later with a single intravenous dose of 10 Lg of immunotoxin there was a significant therapeutic effect
evidenced by the numbers of animals surviving in the therapy group compared with untreated controls
(X2 = 5.348, P = 0.021). These results demonstrate the useful application of human leukaemia xenografts in
SCID mice and the potential therapeutic effect of an anti-CD7 immunotoxin in human T-ALL.
The ability to manipulate an accurate model of human
cancer in an animal host is one way in which developments
in the understanding of tumour origins, progression and
treatment can be advanced. To this end much work has
focused on human tumour xenografts grown in nude mice
(Fogh et al., 1977; Giovanella et al., 1978). Similarly, the
nude mouse has been extensively utilised to study human
leukaemia (Watanabe et al., 1978, 1980), but because the
resultant tumour growth manifests itself either as a solid
mass or as malignant ascites this model bears little resem-
blance to the spectrum of disease seen in man.
The SCID mouse was first described by Bosma et al.
(1983), who reported its potential for the transplantation of
allogeneic haematopoietic cells from Balb/c animals into
these animals. Following this study other workers have
reported the ability to engraft human lymphoid cells and
stem cells to produce normal human lymphoid and myeloid
differentiation in these mice (Kamel-Reid & Dick, 1988;
McCune et al., 1988; Mosier et al., 1988; Mosier, 1990). This
in turn has generated interest in the study of a murine model
of AIDS using HIV-I-infected human haematopoietic cells
(Namikawa et al., 1988; McCune et al., 1990). The first
report of a human leukaemia cell line xenograft into SCID
mice was by Kamel-Reid et al. (1989), resulting in
disseminated growth of a pre-B acute leukaemia cell line.
Subsequently a range of human leukaemias of T-cell and
non-T-cell origin have been demonstrated to display similar
disseminated growth patterns mimicking much more closely
than previous animal models the clinical picture of human
leukaemia (Ghetie et al., 1990; Cesano et al., 1991; Kamel-
Reid et al., 1991; Jansen et al., 1992a; Uckun et al., 1992a).
Other tumour types including Epstein-Barr virus-associated
lymphoproliferative disease (Cannon et al., 1990; Purtillo et
al., 1991; Rowe et al., 1991), T-cell lymphoma (Charley et al.,
1990; Waller et al., 1991) and lung and other solid car-
cinomas (Reddy et al., 1987) have also been successfully
engrafted into SCID mice.
In this report we describe the picture of disseminated
human acute T-cell leukaemia which develops following in-
travenous injection of cells from the CD7+ T-ALL cell line
HSB-2 into SCID mice. We describe the histological and
immunohistochemical findings in tissue sections obtained
from these animals. This murine model was then used to
explore the in vivo therapeutic efficacy of an immunotoxin
constructed with the anti-CD7 monoclonal antibody HB2
conjugated to the ribosome-inactivating protein (RIP)
saporin derived from the soapwort plant Saponaria
officinalis.
Materials and methods
Human acute T-cell leukaemia cell line
The CD7+ T-ALL cell line HSB-2 (Adams et al., 1970) was
maintained in RPMI-1640 medium containing 10% fetal calf
serum (Gibco) and supplemented with 1 mmol of glutamine
and 1 mmol of sodium pyruvate. Cells were maintained in
the logarithmic phase of growth by passage at regular inter-
vals.
Animals
SCID mice (8-10 weeks of age) were obtained from the
breeding colony housed in the Biomedical Research Facility
at Southampton General Hospital. Animals were housed
under sterile conditions in an isolator unit and fed on auto-
claved food and filter-sterilised water. Animals for experi-
mental use were transferred from the isolator unit to
microisolator filter top cages for ease of handling during
experimental procedures. All experimental interventions were
performed within the confines of a laminar flow hood under
aseptic conditions.
T-cell leukaemia inoculation
HSB-2 cells were washed in RPMI and viability checked
using trypan blue dye exclusion. Cells were resuspended in
RPMI to a concentration whereby each animal received the
same volume of inoculum (0.3 ml). Mice were injected intra-
venously into the lateral tail vein. Recipient animals were
observed closely for signs of illness or distress (ruffled fur,
weight loss, tachypnoea) and were killed in the terminal
phase of their illness unless dying spontaneously.
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Pathology
An autopsy was performed on each animal and the macro-
scopic findings recorded. The following tissues were removed
for histological examination and fixed in 10% buffered for-
malin solution: liver, kidneys, lungs, heart, spleen, brain and
both femurs (for bone marrow examination). Femurs were
subsequently decalcified and all tissues were embedded in
paraffin wax prior to sectioning and mounting.
Histology
Tissue sections were routinely stained with haematoxylin and
eosin. Immunocytochemical staining was also performed on
freshly cut tissue sections. A polyclonal anti-human CD3
(Dako) antibody was used to demonstrate human T-cell
infiltration within decalcified femur sections and the anti-
human CD43 monoclonal antibodies MT1 and DFT1 were
used on the other tissue sections. A standard avidin-biotin-
complex (ABC) peroxidase method for immunohistochemical
staining was used and slides were counterstained with
haematoxylin.
Preparation ofthe anti-T-cell immunotoxin HB2-Sap
Monoclonal anti-CD7 antibody HB2 was obtained by injec-
ting 1 x 107 hybridoma cells into the peritoneal cavity of
pristane-primed Balb/c mice. The 7S IgG fraction of ascitic
fluid was isolated by precipitation with 6 M ammonium sul-
phate followed by ion-exchange chromatography on
DEAE-Sepharose and a further gel filtration step on
Sephacryl S200 HR (Pharmacia). The single-chain ribosome-
inactivating protein (RIP) saporin was purified from the
seeds of Saponaria officinalis as described previously (Stirpe
et al., 1983). The conjugation of saporin to the CD7 mono-
clonal antibody was performed as previously described
(Thorpe et al., 1985). Briefly, both the monoclonal antibody
HB2 and saporin were reacted with N-succinimidyl-3-(2-
pyridyldithio)propionate (SPDP) (Pharmacia) to yield 2-
pyridyl disulphide-substituted products. The 2-pyridyl
disulphide-substituted saporin was reduced with 50 mM
dithiothreitol and the reduced product reacted for 24 h at
room temperature with the substituted HB2 antibody.
Immunoconjugate was separated from unreacted free saporin
by gel filtration on Sephacryl S200 HR. Free unconjugated
HB2 antibody was removed by cation-exchange chromato-
graphy on CM-Sepharose. The purity of the final
immunotoxin product was confirmed by SDS-PAGE.
Cytotoxicity ofimmunotoxin in vitro
In vitro cytotoxicity of the HB2-Sap immunotoxin was
assessed in a [3H]leucine incorporation assay that we have
described previously (Flavell et al., 1991). Triplicate cultures
of HSB-2 cells at a density of 1 x 105 cells per well in 96-well
microculture plates were exposed for 48 h at 37°C to
immunotoxin or equimolar concentrations of saporin and
HB2 antibody at each experimental concentration. Cells were
then pulsed for 12 h with 1.0ft Ci of [3H]leucine (TRK 510,
Amersham International, UK) and finally harvested onto
glassfibre filters using a Skatron cell harvester. The amount
of radioactive leucine uptake by cells was measured by scin-
tillation counting using a Packard scintillation counter.
Results obtained for experimental cultures are expressed as a
percentage of the amount of [3H]leucine incorporation
observed in untreated control cultures.
Establishment ofhuman T-ALL in SCID mice
In an initial experiment eight SCID mice were inoculated
with 107 HSB-2 cells intravenously. Five animals were
pretreated with total body irradiation (4 Gy) immediately
prior to inoculation of cells, and three animals received no
irradiation. Disease spread and progression was monitored as
described above. Findings described later revealed that total
body irradiation was unnecessary for successful engraftment
and therefore in all subsequent experiments animals were not
treated with total body irradiation.
Establishing diseaseprogression in SCID mice
In order to monitor the progression of human T-ALL in
SCID mice, 35 animals were injected intravenously with 107
HSB-2 cells. Initially three animals were sacrificed on a
weekly basis and full post-mortem findings and histological
examinations documented. By 6 weeks all animals had
developed leukaemia and had been sacrificed or had died
naturally.
Challenge with graded numbers ofHSB-2 cells
In an attempt to establish a suitable working model for in
vivo immunotoxin experiments, 40 animals were injected in-
travenously with varying numbers of HSB-2 cells ranging
from 104 to 107 cells per animal. Animals were monitored
until showing signs of disease or until dying naturally. Sur-
vival curves were established for each group of animals.
Immunotoxin study with T-ALL in SCID mice
Groups of animals were initially injected intravenously with
106 HSB-2 cells. Seven days later the mice were given a single
10tLg intravenous dose of HB2-Sap immunotoxin (IT)
(equivalent to approximately 0.5 mg kg-') administered in a
200,l volume of PBS. Control animals were either sham
treated with phosphate-buffered saline (PBS) (200pl) or
treated with the monoclonal HB2 antibody also at 10 .tg per
animal (in 200 tLI volume) or with 10jg of a non-targeting
isotype, linker, toxin-matched anti-CD19-saporin
immunotoxin control (BU12-Sap). Similarly, experimental
animals which had not received the HSB-2 leukaemic cells
were treated with immunotoxin, PBS or monoclonal
antibody. Survival curves were plotted and analysed.
Results
The characteristics ofhuman T-ALL in SCID mice
The initial pilot experiment demonstrated that irrespective of
pretreatment with total body irradiation all of the animals
that had been injected with 107 HSB-2 cells developed
disseminated HSB-2 leukaemia. Clinical examination of the
animals revealed that in the terminal stages of disease they
developed weight loss, tachypnoea and ruffling of the fur. In
addition a few animals appeared to have paralysis of the
hind limbs, thought to be due to infiltration of the CNS with
leukaemia. Gross examination of organs at the time of
autopsy demonstrated several abnormalities. The majority of
animals had obvious infiltration of the liver with discrete
areas of solid white tissue replacing normal liver tissue. Renal
involvement was characterised by multiple nodules of tumour
on the renal capsule, which on occasion infiltrated deeply
into the substance of the kidney itself. Solid white infiltrates
were often seen within the lung parenchyma, and pericardial
deposits were obvious in at least two animals. There was no
obvious lymph node enlargement in any of the animals,
although one mouse had a large mediastinal tumour similar
in character to the mediastinal enlargement seen in some
patients with T-cell lymphomas and leukaemias. The spleens
were small and demonstrated no obvious leukaemic
infiltration. The brains similarly showed no macroscopic
abnormality even in the presence of neurological symp-
toms.
Histological examination of tissue demonstrated several
abnormalities listed below. Femur secretions revealed that
the bone marrow morphology in diseased animals consisted
of a mononuclear cell infiltrate replacing all of the normal
haematological cells and ablating marrow spaces. The liver
showed disseminated disease throughout the normal paren-
chyma. Kidney involvement was apparent as either capsularHB2 - SAPORIN IN HUMAN T- ALL 281
nodules or perivascular infiltration, a pattern that was similar
to that seen in lung. The spleen was apparently uninvolved.
Sections of brain demonstrated a meningeal infiltration of
leukaemic cells with a similar pattern to the CNS infiltration
seen in humans with leukaemia.
Immunohistochemical staining of tissues demonstrated the
leukaemic infiltration of organs more accurately while also
confirming that infiltrating cells were indeed human. Normal
SCID mouse tissues demonstrated no cross-reactivity with
the antibodies used. The polyclonal CD3 antibody was used
on femur sections and confirmed the cellular infiltrate to be
human T cell in origin (Figure la and b). Likewise, the other
organ tissue sections, when stained using the CD43
antibodies, confirmed that the leukaemic infiltrates seen in
the H&E sections documented above were indeed human
T-ALL in origin (Figure lc-f).
The results from those animals that were serially sacrificed
to monitor the progress of disease are shown in Figure 2.
Bone marrow infiltration was the first event to occur and
could be detected as early as 7 days from the time of the
initial inoculation. With the passage of time there was a
progressive dissemination of the leukaemic cells such that at
the stage when all the animals were dying at 6 weeks they all
had multiorgan involvement. Leukaemia was universally seen
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Figure 1 Histopathology of HSB-2 human T-ALL in SCID mice. a, Photomicrograph of femur section demonstrating the diffuse
monomorphic leukaemic infiltrate staining positive with anti-human CD3 polyclonal antibody. Immunoperoxidase x 125. b,
High-power view of bone marrow leukaemic infiltrate showing strong reactivity to anti-CD3 antibody. Immunoperoxidase x 200.
c, Immunohistochemical staining of liver with anti-CD43 antibody showing diffuse leukaemic deposits within the normal
parenchyma. Immunoperoxidase x 125. d, Replacement ofnormal renal architecture with heavy CD43-positive leukaemic infiltrate.
Immunoperoxidase x 62. e, Strong CD43 expression in a leukaemic infiltrate surrounding a pulmonary vessel. Iminunoperoxidase
x 125. f, Immunohistochemical staining (CD43) of a meningeal leukaemic deposit overlying the cerebral cortex. Immunoperoxidase
x 125.282 B.J. MORLAND et al.
in all animals given an i.v. inoculum of I07 HSB-2 cells.
The result of administering graded numbers of HSB-2 cells
to SCID mice is shown in Figure 3. There is a clear dose
effect seen, with all animals given the highest cell inoculum
(107) dying by 52 days (mean survival 43 days), while in
animals given 104 cells per animal only one death occurred
by 150 days.
In vitro cytotoxicity ofHB2-Sap immunotoxin
Triplicate cultures of 1 x 105 HSB-2 cells were exposed for
48 h to increasing concentrations of HB2-Sap immunotoxin
(10-12 to 10i7 M). Identical cultures were set up with
equimolar mixtures of saporin and HB2 antibody and with
HB2 antibody alone. Cultures of untreated controls were set
up with medium alone. After 48 h of exposure [3H]leucine
uptake was evaluated in all cell cultures and results expressed
as a percentage of the control levels, as shown in Figure 4.
An IC50 of 4.5 pM was obtained for the HB2-Sap immuno-
toxin, whereas the IC50 for the equimolar concentration of
saporin and HB2 antibody was 0.14 JLM, representing a
31,000-fold increase in toxicity. The native HB2 antibody at
all concentrations had no effect on HSB-2 cells.
Two experiments were performed in which the CD7-
specific delivery of HB2-Sap immunotoxin was demon-
strated. In a similar group of experiments to those described
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Figure 2 Progression of disease in SCID mice injected with 107
HSB-2 cells. The proportion of animals with histological evidence
of HSB-2 infiltration of various organs is shown in relation to the
age of the animal at the time of death.
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Figure 3 The effect of giving graded doses of HSB-2 cells by
intravenous injection into SCID mice. Results are expressed as
the percentage of surviving animals with time in mice receiving
(- *) 107cells, (TV--) O6cells, (A-- ) 105cells and
(U U) 104 cells per animal. Control animals (* *) received
PBS alone.
above the immunotoxin HB2-Sap was added to cultures of
the CD7- cell line HL60 in concentrations varying from
10-12 to 10-7M. Cells were also exposed to saporin in the
same molar concentrations and to control medium only.
Exposure was for 48 h and [3H]leucine uptake was performed
and analysed as described above. The- immunotoxin demon-
strably failed to deliver an effective dose of saporin to HL60
cells (IC50 for HB2-Sap IT 0.025gLM vs 0.043 ILM for saporin
alone) (Figure 5).
In a second specificity experiment an attempt was made to
block the binding of the HB2-Sap immunotoxin to HSB-2
cells by incubating in the presence of increasing concentra-
tions of the native anti-CD7 antibody HB2. HSB-2 cells were
exposed for 48 h to a fixed concentration of HB2-Sap
immunotoxin (10-9 M) in the presence of increasing concent-
rations of HB2 antibody (10-" to 10-7 M), then [3H]leucine
incorporation was determined. The resulting dose-response
curve demonstrated that in the presence of 10-7 M HB2 the
cytotoxic effect of the immunotoxin was almost completely
abrogated (Figure 6).
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Figure 4 Protein synthesis levels in HSB-2 cells exposed to
various concentrations of HB2-Sap immunotoxin (V V)
(ICn 4.5 pmol), an equimolar solution of free saporin and HB2
MAb (U U) (IC50 0.14pmol) and HB2 MAb alone
(A- ) (s.d.<5% for all points).
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Figure 5 Protein synthesis levels in the CD7- cell line HL60
exposed to various concentrations of HB2-Sap immunotoxin
(V V), an equimolar solution of free saporin and HB2 MAb
(U U) and HB2 MAb alone (A A) (s.d. <5% for all
points).
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Figure 6 Protein synthesis levels' in HSB-2 cells exposed to
HB2-Sap immunotoxin at 10-9M (A^ *) in the presence of
increasing concentrations of HB2 MAb.
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Figure 7 The in vivo effect of HB2-Sap immunotoxin on SCID
mice tranplanted with HSB-2 cells. Animals were injected i.v.
with 106 HSB-2 cells and 8 days later received a single i.v.
injection of 10jg of HB2-Sap immunotoxin (V V), 10fig of
HB2 MAb (A---A) or PBS only (- U). Surviving animals are
plotted against time.
The effect ofHB2-Sap immunotoxin in SCID mice
transplanted with HSB-2 T-ALL cells
The survival data for the animals are shown in Figure 7. At
the termination of the experiment at 150 days there had been
five deaths in the immunotoxin-treated group of animals
compared with nine deaths in the control group. Post-
mortem and histological examination of tissues from animals
surviving 150 days failed to demonstrate any evidence of
leukaemic infiltration. Using Mantel-Cox log-rank analysis
the survival of immmunotoxin-treated animals was signifi-
cantly greater than that of controls (X2 = 5.348, P = 0.021).
No difference in survival was observed between PBS control
and BU12-Sap immunotoxin-treated animals (data not
shown). Animals treated with monoclonal HB2 antibody
alone had no overall prolongation in survival (X2 = 2.124,
P = 0.145), however it was interesting to note that there was
a delay in the time it took for animals to die compared with
controls. This result was confirmed in subsequent
experiments, and in addition identical survival curves were
obtained with a mixture of free saporin and monoclonal HB2
antibody in an amount equivalent to the immunotoxin (data
not shown). We assume that this may be due to the recogni-
tion and destruction of antibody-coated leukaemic cells by
NK cells present in the SCID mice (Dorshkind et al., 1985)
though this is conjecture and we have no experimental
evidence for this.
Discussion
Our study has demonstrated that the intravenous administra-
tion of the human T-ALL cell line HSB-2 into SCID mice
produces a disseminated pattern of disease that closely
mimics the pattern of disease observed in humans with acute
lymphoblastic leukaemia. We were able to show that the
anti-CD7-saporin immunotoxin HB2-Sap exerted a selective
and potent cytotoxic effect against CD7+ HSB-2 cells in vitro
and that this also translated into a significant in vivo
therapeutic effect in HSB-2-bearing SCID mice. Thus, there
was a prolonged survival of HSB-2-bearing animals given a
single 10 ig i.v. dose of HB2-Sap IT.
The observation that human acute leukaemia cells can be
engrafted into SCID mice to produce a pattern of disease
with biological similarities to human leukaemia is an impor-
tant advance in our ability to be able to observe and
manipulate in vivo therapeutic interventions. In nude mouse
experimental models of human leukaemia, localised growth
of solid tumours occurs (Dillman et al., 1985) and only a
limited degree of extrapolation is possible to the disseminated
pattern of disease seen in humans. The nude mouse is
therefore limited to the information it can provide with
respect to the biology and therapy of human leukaemia. The
hope is that the SCID mouse model will provide a tool to aid
the closer understanding of the complex in vivo interactions
involved in disease states such as this.
One potential role for the SCID mouse model of
leukaemia is in the assessment of novel therapeutic ap-
proaches such as the use of targeted immunotherapy. In a
previous study (Flavell et al., 1991) we showed that the
ribosome-inactivating protein saporin has potent in vitro
cytotoxicity when targeted with a bispecific antibody to the
CD7 surface antigen of HSB-2 cells. In the present study we
have clearly demonstrated the effective and selective in vitro,
cytotoxicity of an immunotoxin constructed with the anti-
CD7 monoclonal antibody HB2 and saporin. Other workers
have described the potency of immunotoxins constructed
with the plant toxin ricin and anti-CD7 monoclonal anti-
bodies (Vallera et al., 1983; Myers et al., 1984; Fishwild et
al., 1992), and with the single-chain ribosome-inactivating
protein pokeweed antiviral protein (PAP) (Ramakrishnan &
Houston, 1984). The immunotoxin described by Ramakrish-
nan and Houston (1984) was constructed with the anti-CD7
monoclonal antibody 3A1 and PAP, and when directed
against HSB-2 cells in vitro gave an IC50 of 0.11 nM. Our
immunotoxin HB2-Sap gave an IC50 of 4.5 pM, similar to the
figure (6.7pM) reported by Fishwild et al. (1992).
Interpretation of cytotoxicity between different
immunotoxins needs to be examined with caution however.
There are a number of possible reasons as to why our
anti-CD7-saporin IT HB2-Sap appears more potent than
some of the other published anti-CD7 ITs constructed with
different toxins. Firstly, it may be that the HSB-2 target cells
used in our studies may be intrinsically more sensitive to the
action of immunotoxins generally. Only by comparing all the
other ITs directly with each other against the same target cell
line can this issue be resolved. Also, antibody affinity and the
locality of the epitope recognised by the antibody in the
target molecule can have marked effects in immunotoxin
potency (Youle & Neville, 1982), and equally these con-
siderations may be responsible for the observed differences in
potency.
In previous studies in our laboratory utilising a bispecific
antibody, one Fab arm of which was constructed with the
same anti-CD7 antibody HB2 and the other Fab arm with an
anti-saporin antibody (HB2 x DB7-18), the delivery of
saporin to HSB-2 cells was less efficient with an achieved IC50
of 0.23 nM (expressed as the concentration of free saporin in284 B.J. MORLAND et al.
the system) (Flavell et al., 1991). The improved effectiveness
of the HB2-Sap immunotoxin over the bispecific antibody
HB2 x DB7-18 is probably because the bispecific antibody
attaches to the cell surface univalently and therefore has a
lower binding avidity and also does not cross-link adjacent
CD7 molecules on the cell surface. In contrast, the
immunotoxin having two intact Fab arms with the same
anti-CD7 specificity will bind with high avidity and moreover
will cross-link adjacent CD7 molecules, resulting in more
efficient internalisation by receptor-mediated endocytosis.
The therapeutic use of ricin immunotoxins in T-cell
leukaemia has been described in nude mouse models of
localised tumour growth (Weil-Hilman et al., 1987; Leonard
et al., 1988) and more recently Jansen et al. (1992b) have
described the in vivo use of an anti-CD7 deglycosylated ricin
A-chain immunotoxin DA7 in SCID mice bearing the CD7+
T-ALL cell line MT-ALL. In this experimental therapy
model, SCID mice were injected intravenously with 5 x 107
MT-ALL cells. Eight days following tumour cell injection
therapy animals were given five consecutive daily intra-
peritoneal injections of 10 ,g of DA7 immunotoxin. This
study demonstrated a highly significant anti-leukaemic effect
of the immunotoxin compared with control animals. Similar
results have been demonstrated in a SCID murine model of
pre-B ALL using an anti-CD19 pokeweed antiviral protein
immunotoxin (Uckun et al., 1992a). In the present study we
have clearly demonstrated a significant therapeutic effect of
the HB2-Sap IT in SCID mice bearing the human T-ALL
cell line HSB-2. Moreover, our therapy study utilised only a
single Ojig dose of IT given on day 8 following leukaemia
cell injection, a time at which we have demonstrated that
animals have established disease. This response compares
with the other in vivo SCID studies described above in which
multiple doses of IT therapy have been shown to achieve
good therapeutic results. Also, in the study of Uckun et al.
(1990), since the immunotoxin therapy commenced 1 day
after the leukaemic cell inoculum, it could be argued that
insufficient time was allowed for the animals to develop
leukaemia prior to treatment and that this may have
influenced the responses demonstrated.
The highly selective and highly cytotoxic nature of
immunotoxins makes them ideal potential candidates for
improving the therapy of haematological malignancies such
as acute leukaemias and lymphomas. To date, however, only
a limited number of clinical data have been collected in the
systemic application of immunotoxins in this field. The use of
immunotoxins in purging the bone marrow of autologous
transplantation patients with ALL has been extensively inves-
tigated and is quite widely used in clinical practice (Uckun et
al., 1990). The clinical systemic use of immunotoxins in
haematological malignancy is much less well researched and
centres around preliminary phase I data (Laurent et al., 1986;
Vitetta et al., 1991; Grossbard et al., 1992; Uckun et al.,
1992b). Little useful clinical information on the likely efficacy
of such treatment in humans therefore currently exists but is
slowly accumulating. Future phase II and III trials will be
necessary in order to determine the precise role, if any,
immunotoxins may have in the advancement of therapy in
haematological malignancy.
In conclusion therefore we have been able to demonstrate
the widespread dissemination of human T-ALL in SCID
mice producing a pattern of disease mimicking the natural
history of acute lymphoblastic leukaemia in man. Such a
model may have many potential uses in the investigation of
therapeutic and pharmacokinetic studies and the research of
new anti-leukaemic agents. Using this animal model we have
been able to show a significant therapeutic effect from a
single intravenous injection of a CD7/saporin immunotoxin.
Our results support the hopes that such agents may play a
useful future role in the clinical management of patients with
T-ALL.
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